1. Home
  2. WES vs INSM Comparison

WES vs INSM Comparison

Compare WES & INSM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • WES
  • INSM
  • Stock Information
  • Founded
  • WES 2007
  • INSM 1988
  • Country
  • WES United States
  • INSM United States
  • Employees
  • WES N/A
  • INSM N/A
  • Industry
  • WES Natural Gas Distribution
  • INSM Biotechnology: Pharmaceutical Preparations
  • Sector
  • WES Utilities
  • INSM Health Care
  • Exchange
  • WES Nasdaq
  • INSM Nasdaq
  • Market Cap
  • WES 15.7B
  • INSM 12.6B
  • IPO Year
  • WES 2008
  • INSM 2000
  • Fundamental
  • Price
  • WES $37.10
  • INSM $65.08
  • Analyst Decision
  • WES Hold
  • INSM Strong Buy
  • Analyst Count
  • WES 5
  • INSM 16
  • Target Price
  • WES $38.60
  • INSM $95.36
  • AVG Volume (30 Days)
  • WES 1.1M
  • INSM 2.5M
  • Earning Date
  • WES 05-07-2025
  • INSM 05-08-2025
  • Dividend Yield
  • WES 9.81%
  • INSM N/A
  • EPS Growth
  • WES N/A
  • INSM N/A
  • EPS
  • WES 3.34
  • INSM N/A
  • Revenue
  • WES $3,634,610,000.00
  • INSM $381,030,000.00
  • Revenue This Year
  • WES $6.26
  • INSM $30.36
  • Revenue Next Year
  • WES $4.12
  • INSM $115.55
  • P/E Ratio
  • WES $11.11
  • INSM N/A
  • Revenue Growth
  • WES 11.48
  • INSM 20.77
  • 52 Week Low
  • WES $33.60
  • INSM $21.92
  • 52 Week High
  • WES $43.33
  • INSM $84.91
  • Technical
  • Relative Strength Index (RSI)
  • WES 46.48
  • INSM 35.80
  • Support Level
  • WES $35.25
  • INSM $63.81
  • Resistance Level
  • WES $36.39
  • INSM $73.39
  • Average True Range (ATR)
  • WES 0.96
  • INSM 2.53
  • MACD
  • WES -0.03
  • INSM -0.38
  • Stochastic Oscillator
  • WES 46.60
  • INSM 13.26

About WES Western Midstream Partners LP Common Units Representing Limited Partner Interests

Western Midstream Partners LP is a USA-based company which own, operate, acquire and develop midstream energy assets. The company through its subsidiary is engaged in the business of gathering, processing, compressing, treating and transporting natural gas, condensate, NGLs and crude oil. It owns or has investments in assets located in the Rocky Mountains (Colorado, Utah, and Wyoming), the Mid-Continent (Kansas and Oklahoma), North-central Pennsylvania and Texas.

About INSM Insmed Incorporated

Insmed Inc is a biopharmaceutical company transforming the lives of patients with serious and rare diseases. The company's first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), approved in the US for the treatment of Mycobacterium Avium Complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. It is also developing Brensocatib, an oral reversible dipeptidyl peptidase 1 inhibitor for bronchiectasis and other neutrophil-mediated diseases, and Treprostinil Palmitil Inhalation Powder, an inhaled treprostinil prodrug for pulmonary hypertension linked to interstitial lung disease and pulmonary arterial hypertension.

Share on Social Networks: